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Abstract
Background: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate
(EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting.
Methods: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were
included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was
assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data.
Results: Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were
Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients
presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number
was 4 [1–9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median
number of EM cycles was 5 [1–19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of
13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20–31) with a
36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25–4.3) and
11.2 (95 %CI: 9.3–12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In
multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes
resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the
presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP
independent prognostic factors. Treatment was globally well tolerated. Most common grade 3–4 toxicities were
neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia
(0.4 %). Thirteen patients (5 %) developed febrile neutropenia.
Conclusion: EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical
practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of
EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites
could represent useful predictive and prognostic factors.
Keywords: Breast cancer, Eribulin mesylate, Efficacy, Safety
* Correspondence: William.jacot@icm.unicancer.fr
6Département d’Oncologie Médicale, Institut régional du Cancer de
Montpellier (ICM), 208, rue des Apothicaires, 34298 Montpellier Cedex 5,
France
Full list of author information is available at the end of the article
© 2015 Dell’Ova et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dell’Ova et al. BMC Cancer  (2015) 15:659 
DOI 10.1186/s12885-015-1673-3
Background
Breast cancer represents the second most common can-
cer worldwide and the most frequent cancer in women,
with an estimated 1.67 million new cases in 2012 (25 %
of all cancers) [1, 2]. Anthracyclines and taxanes remain
the standard as first-line metastatic breast cancer (MBC)
treatment [3]. However, anthracyclines are often given in
a neoadjuvant/adjuvant situation and their use in MBC
should take into account the risk of cumulative cardiac
toxicity. Taxanes are today extensively included in the
early breast cancer adjuvant chemotherapy regimens and
expose the patients to the risk of peripheral neurotox-
icity. Other molecules such as the capecitabine, the lipo-
somal doxorubicin, the pegylated liposomal doxorubicin,
the gemcitabine and the vinorelbine, have also been reg-
istered, more recently, in the MBC setting [4]. However,
no clear standard of care has been validated after first-
line treatment failure, and further treatment lines de-
pend mainly on the drugs previously used, their residual
toxicities, the performance status of the patient, and the
biology and metastatic spreading of the tumour.
Eribulin mesylate (EM, Halaven®, E7389) is a new drug
indicated for patients with MBC previously treated with
an anthracycline and a taxane in the adjuvant or meta-
static setting, and at least two chemotherapeutic regi-
mens for the treatment of the metastatic disease [5]. It is
a synthetic analogue of the marine natural product hali-
chondrin B, isolated from the Japanese marine sponge
Halichondria okadai [6, 7]. EM is a non-taxane micro-
tubule dynamics inhibitor; indeed, its site and mechan-
ism of action are different from other tubulin-targeting
agents such as taxanes and vinca-alcaloïds [8]. EM in-
hibits microtubule polymerisation without affecting their
depolymerisation, resulting in non-productive aggregates
which induce an irreversible mitotic block at the G2-M
phase, and leading to apoptosis [9]. The phase III pivotal
open-label randomised study EMBRACE compared EM
monotherapy versus treatment of physician’s choice
(TPC) in patients with MBC. This trial showed the effi-
cacy and tolerability of this molecule, leading to its ap-
proval by the US Food and Drug Administration (FDA)
on November 15th, 2010. EMBRACE demonstrated a
significant and clinically improvement in overall survival
(OS) under EM treatment compared with the TPC in
this setting. However, the vast majority of the patients
included in this trial had previously been treated with
capecitabine. Another phase III trial comparing EM
versus capecitabine [10] in a population of 1102 patients
previously treated with anthracyclines and taxanes did
not show a statistically significant superiority of EM over
capecitabine in terms of progression-free survival (PFS)
and OS. However, considering the EMBRACE trial [11]
and the toxicity profile in the Kaufman study, EM
appears as a new therapeutic option in patients with
metastatic or locally advanced breast cancer, and pre-
treated with taxanes- and anthracyclines. Despite its
extensive use in these patients, EM clinical efficacy and
safety in the “real-world” patient population still need to
be clearly evaluated.
This retrospective, international study aimed at evalu-
ating EM activity and safety in a routine clinical setting,
and at comparing our results with the published clinical
data about EM.
Methods
Study design
Four centres participated in this retrospective clinical
study, three centres in France (Institut régional du
Cancer de Montpellier [ICM], Montpellier, Institut
Claudius Regaud, Toulouse, and Centre Georges-François
Leclerc, Dijon), and one centre in Switzerland (CHU
Vaudois, Lausanne). An Access database was created to
collect retrospective data using different panels: patients’
identification, tumour histology, previously delivered
treatments and regimens, initial assessment, initial
biology, EM chemotherapy-related data (delivered EM
dose and cause of diminution, number of cycles ad-
ministered, toxicities and side effects), efficacy and
follow-up data. The tumour response was assessed
every 3 cycles of treatment. Tumours were considered
as ER and PR positive when > 10 % tumour cells were
stained by immunohistochemistry (IHC). HER2 status
was determined based on HER2 protein expression level
by IHC. Tumours with HER2 scores of 0 and 1+ were
considered as HER2 negative. In tumours with equivocal
HER2 IHC test results (2+), gene amplification was evalu-
ated using fluorescent (FISH) or chromogenic (CISH) in
situ hybridization. Specimens with HER2 3+ scores were
considered as HER2 positive. The Database locking and
patients’ follow-up was scheduled for April 7th, 2014. This
study was reviewed and approved by the respective
Institutional Review Boards (Dijon, Toulouse and
Montpellier Cancer Centres, and Lausanne CHUV, ID
number ICM-URC-2014/73). Considering the retrospect-
ive, non-interventional nature of this study evaluating an
approved drug, no consent was deemed necessary by the
clinical research review board of Montpellier cancer
centre (sponsor of the study).
Patients
All patients affected by a metastatic or locally advanced
breast cancer treated with EM between March 28th,
2011 and January 15th, 2014 in one of the participating
centres, were included in our retrospective analysis. Pa-
tients with EM treatment initiated in other centres, and
who received only one EM injection or cycle in a partici-
pating centre, were not considered suitable for this study
due to the lack of data.
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Treatment
Eribulin mesylate was administrated intravenously over
2 to 5 minutes on days 1 and 8 of a 21-day chemother-
apy cycle, according to the product guidelines. The EM
treatment was generally administered at the standard
dose of 1.4 mg/m2. It was reduced in case of hepatic or
moderate renal impairments: a -20 % reduction of the
recommended EM dose (1.1 mg/m2) was applied for
patients with mild hepatic impairment (Child-Pugh A)
or moderate renal impairment (creatinine clearance of
30–50 mL/min), and a −50 % reduction (0.7 mg/m2) was
administered in patients with moderate hepatic impair-
ment (Child-Pugh B). Clinical and radiological assess-
ment of the tumour response was performed according
to each centre standard of care, most of the time every
3 cycles of treatment (every 9 weeks). Clinical and bio-
logical assessment of toxicity was performed at each
clinical visit, i.e. at day 1 and day 8 of each 21-day cycle.
Primary and secondary granulocyte-colony stimulating
factor (G-CSF) prophylaxis was delivered according to
each centre’s practice.
Efficacy assessment
Clinical and radiological efficacy assessment was per-
formed every 3 cycles by a medical oncologist during the
whole treatment period. Response and progression eval-
uations were performed using the RECIST version 1.1
criteria [12]. For each evaluation, treatment response
was determined as such: complete response (CR), partial
response (PR), stable disease (SD), progressive disease
(PD), or not established (NE). Clinical proposal following
assessment (continued treatment, dose reduction or
treatment discontinuation) was recorded, together with
the reasons of treatment discontinuation (toxicity, evolu-
tion, death or other).
Safety assessment
Clinical and biological toxicities were retrospectively
identified and graded according to the Common
Terminology Criteria grid for Adverse Events (CTCAE)
version 4.03 at each clinical visit, using the patients’ clin-
ical charts. Interdose complications were recorded: treat-
ment delay (duration and cause), treatment cancellation
and reason, hospitalization (duration and cause), duration
of antibiotic treatment, and need and number of Red
Blood Cells (RBC) and/or platelet concentrates in case of
transfusion.
Statistical analysis
For the descriptive analysis, quantitative variables were
presented for each group and for the overall population
as mean, variance, standard deviation, minimum, max-
imum, and median. Quantitative criteria were compared
using the Kruskal-Wallis test. Qualitative variables were
presented as numbers and frequencies for each category
of the variable. Qualitative criteria were compared using
the chi2 or by the Fisher exact tests when the chi2 test
was not applicable. The primary objective of the study
was to assess overall survival until progression. Survival
estimates were calculated using the Kaplan-Meier
method. The time to progression was defined for each
patient as the time from the first cycle until objective
tumour progression (TTP does not include deaths). The
secondary objective was overall survival (OS), defined as
the time from the first cycle of treatment until death
from any cause. For the clinicopathological features, uni-
variate analyses to compare clinical benefit and no clin-
ical benefit were performed using Pearson’s 2 or Fisher’s
exact tests for categorical variables, and the two-sample
Wilcoxon test for all continuous variables. Categorical
covariates analysis were ECOG Performance Status (0–1
vs. 2–3), hormone receptors (HR- vs. HR+), and age
(≤50 vs. > 50 years), HER2+ over-expression (no/yes),
number of prior chemotherapy (≤4 vs. > 4 lines) and
different metastasis localization (visceral metastases,
liver, bone, lymph nodes, lung, brain, serous or skin
metastases), and response under taxane chemotherapy
(CR/PR/SD vs. PD/NE). Differences were considered
statistically significant when p < 0.05. Significant factors in
the univariate analyses were included in a multivariate
logistic regression analysis to identify independent
predictors of the clinical benefit.
For the multivariate analysis using the Cox’s propor-
tional hazard model to define independent prognostic
factors for PFS, the variables included in the logistic
regression were used. The hazard ratio and the 95 %
confidence interval (CI) were also estimated.
Different bases transfers were made through
STAT-TRANSFER version 9 and data were analysed
using the STATA® version 13.0 software.
Results
Patients
Two hundred and fifty-eight patients were included in
our study. Main clinic pathological characteristics of the
population are presented in Table 1. Median age at breast
cancer diagnosis and at EM initiation was 50 (18–80) and
59 years old (22–85), respectively. Patients’ ECOG per-
formance status at EM initiation was 0 or 1 in 79.9 % of
the cases. Biological subtypes were classical for this popu-
lation, as 73.3 % of the tumours were Hormone Receptor
(HR)-positive, 10.2 % were HER2-positive, and 22.5 %
were triple negative (TN). Disease extension was typical of
late stage tumours: 86.4 % of the patients presented with
visceral metastases, mainly in the liver (67.4 %). Patients
with HR-positive tumours had previously been treated
with at least one hormonal therapy line for metastatic
disease in 97.3 % of the cases. Patients were heavily
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pretreated with chemotherapy (median number of
previous metastatic regimens was 4 [1–9]) in the
metastatic setting. All patients had previously received
anthracycline- and/or taxane-based treatments (94.6 %
of the patients had previously received anthracycline
and 98.1 % taxane regimen in neoadjuvant/adjuvant
and/or metastatic chemotherapy settings). The majority
(82.1 %) of patients pretreated with taxanes showed
primary taxane sensitivity as defined by CR, PR or
SD > 6 months under taxane treatment in metastatic
setting. Twenty-five of the 26 patients presenting
HER2-positive tumours received trastuzumab con-
comitantly with EM administration.
Eribulin mesylate chemotherapy
The median number of delivered EM cycles was 5 (1–19)
(Table 2). EM was first administered at the full recom-
mended dose (1.4 mg/m2) in 79.1 % of patients. Causes of
dose reductions at treatment initiation were due to liver
function impairment in 57.7 %, persistent haematological
toxicity in 11.5 % and other causes in 13.5 %; cause of dose
reduction was not indicated in 17.3 % of cases. Dose
reduction under treatment was due to haematological
toxicity (all grades) in 20.2 % of cases, liver toxicity
in 13.2 % of cases and to other causes (14.3 %). The
relative dose intensity was 0.917 (0.165–1.22). Two
hundred and thirty-six (91 %) patients had discontin-
ued EM treatment at the date of analysis. The most
common cause of treatment discontinuation was dis-
ease progression (75 %), followed by toxicity (13.1 %),
and patient’s death (8.1 %); also, 7.2 % of the patients
discontinued EM treatment due to other causes such
as patient’s or medical decision.
Table 1 Main patient and tumour characteristics (n = 258)
Characteristics
Median age at diagnosis; years (range) 50 (18–80)
Histological type of primary tumour; n (%)
Ductal 228 (88.4)
Lobular 21 (8.1)
Other subtypes 9 (3.5)
Tumour subgroup; n (%)
ER-positive 184 (71.32)
PR-positive 122 (47.29)
HR-positive 189 (73.3)
HER2-positive 26 (10.2)
Triple negative 58 (22.5)
ECOG performance status (%)
0 73 (28.3)
1 133 (51.6)
2 46 (17.8)
3 6 (2.3)
Previous chemotherapy for (neo) adjuvant/advanced disease
Anthracyclines; n (%) 244 (94.6)
Taxanes; n (%) 253 (98.1)
Capecitabine; n (%) 234 (90.7)
Median prior lines of chemotherapy in the metastatic
setting (range)
4 (1–9)
Best response under previous taxane therapy; n (%)
Complete response 20 (7.8)
Partial response 112 (43.8)
Stable disease 78 (30.5)
Progressive disease 33 (12.9)
Not evaluable 13 (5.1)
Missing 2
Hormonal therapy
Prior hormonal therapy (HR+ tumours; n [%]) 184 (97.3)
Metastatic sites; n (%)
Visceral metastases 223 (86.4)
Liver 174 (67.4)
Node 118 (45.7)
Lung 98 (38.0)
Brain 41 (15.9)
Serous 55 (21.3)
Skin 31 (12.0)
Bone 176 (68.2)
Other sites 26 (10.1)
Table 2 Efficacy and drug exposure
Objective response rate; n (%) 65 (25.2)
Median duration of objective response, months 4.4 (95 %CI: 3.4–4.8)
Best overall response
Complete response; n (%) 1 (0.4)
Partial response; n (%) 64 (24.8)
Stable disease (>6 months); n (%) 28 (10.9)
Clinical benefit rate, % (95 %CI) 36.1 (30.2–42.2)
Progressive disease; n (%) 157 (60.9)
Not established; n (%) 8 (3.1)
Median time to progression, months ( 95 %CI) 4 (3.3–4.3)
Overall survival, months (95 %CI) 11.2 (9.3–12.1)
One- year overall survival rate,% (95 %CI) 45.5 % (38.3–52.4)
18-month overall survival rate, % (95 %CI) 23.1 % (16.3–30.6)
2-year overall survival rate, % (95 %CI) 8.5 % (2.2–20.3)
Drug exposure
Median EM cycles delivered; n (range) 5 (1–19)
Dose reductions at initiation (%) 20.9
Relative dose intensity (range) 0.92 (0.17–1.22)
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Efficacy
At the time of analysis, after a median follow-up of
13.9 months (95 %CI: 11.66–15.60), 42.3 % of the pa-
tients were still alive. Death was mainly related to dis-
ease progression (PD, 95.1 %). Toxic death was reported
in 2 cases (1.4 %) and was related to intercurrent dis-
eases in 5 cases (3.5 %). Concerning treatment and pro-
gression, 38 % of the patients were still under treatment
and 55.5 % reported disease progression. One patient
presented a complete response to treatment and 64 pa-
tients (24.8 %) showed a partial response (PR). Thus, the
objective response rate was 25.2 % (95 %CI: 20–31). The
median duration of objective response was 4.36 months
(95 %CI: 3.38–4.82). Moreover, a disease stable for at
least 6 months (SD) was observed in 28 patients
(10.9 %) and 157 (60.8 %) showed PD. The tumour
response could not be evaluated in 8 patients (3.1 %)
due to premature discontinuation of the treatment re-
lated to toxicity. The clinical benefit rate, defined as
CR rate, PR rate and SD during at least 6 months,
was 36.1 % (Table 2). Median TTP and OS were 3.97
(95 %CI: 3.25–4.3) and 11.2 (95 %CI: 9.3–12.1)
months, respectively (Figs. 1 and 2 respectively).
Twelve-, 18- and 24-month overall survival rates were
45.5 % (95 %CI: 38.34–52.36), 23.13 % (95 %CI:
16.34–30.63) and 8.5 % (95 %CI: 2.21–20.30), respectively
(Fig. 2).
Safety
The EM treatment was globally well tolerated. Table 3
summarizes the main grade 3–4 toxicities reported in
our population. The most commonly reported toxicities
were asthenia (60.9 %), peripheral neuropathy (43 %),
neutropenia (38.4 %), alopecia (19.4 %), nausea (10.5 %)
and thrombocytopenia (10.5 %). Major toxicities were
of grade 3 (39.5 %) and grade 4 (17 %), and were as
follows: neutropenia (20.9 %), peripheral neuropathy
(3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %),
and thrombocytopenia (0.4 %). Thirteen patients (5 %)
developed febrile neutropenia.
A treatment delay was reported in 69 patients
(26.7 %). The average number of days of report was 14.9
(SD σ = 16.8) with a median number of 8 days (3–130
days). The delay was mostly due to treatment toxicities
(60.9 %). Primary G-CSF prophylaxis was used in 15.1 %
of the patients and as secondary prophylaxis in 12.4 % of
the cases. Antibiotics during EM treatment were used
for 17 % of patients, and red blood cells and platelet
concentrates transfusions in 6.2 and 0.4 %, respectively.
Hospitalisation was required for 17.8 % of the patients
due to cancer-related complications in 52.2 % of cases,
treatment toxicity in 34.8 % and other causes in 37.0 %.
Predictive and prognostic factors
Response and survival rates were evaluated in regards of
the usual prognostic factors to identify relevant prognos-
tic and predictive factors affecting this population. Using
a logistic regression analysis, HER2 positivity was signifi-
cantly associated with higher CBR (HR = 0.38, p = 0.02);
the presence of serous metastases was of borderline
significance (HR = 0.55, p = 0.052), while a TN status and
the presence of lung metastases were significantly
Fig. 1 Time to progression
Fig. 2 Overall survival
Table 3 Main toxicity in 258 patients according to cTcAE version
4.03
Grade 3–4 toxicities; n (%)
Anemia 4 (1.6)
Neutropenia 54 (20.9)
Thrombocytopenia 1 (0.4)
Liver dysfunction 2 (0.8)
Peripheral neuropathy 10 (3.9)
Febrile neutropenia 13 (5.0)
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associated with lower CBR rates (HR = 2.04, p = 0.044
and HR = 2.16 and p = 0.006, respectively). The achieve-
ment of a clinical benefit under a previous taxane
therapy was of borderline significance (p = 0.054). In
multivariate analysis, HER2 positivity (OR = 0.26; 95 %CI
0.10–0.63) was an independent favourable predictive fac-
tor, while the presence of lung metastases (OR = 2.49;
95 %CI 1.43–4.61) and the inability to achieve a clinical
benefit under a previous taxane therapy (OR = 2.36;
95 %CI 1.11–5.03) were independently associated with a
lower CBR.
Using the Cox regression model, a difference was ob-
served regarding TTP: in univariate analysis, HR positivity
and the presence of serous metastases were significantly
associated with a longer TTP, while a TN status, the in-
ability to achieve a clinical benefit under a previous taxane
therapy and the presence of lung metastases were
significantly associated with a shorter TTP. In multi-
variate analysis, HR positivity (HR = 0.68; 95 %CI
0.51–0.92), the presence of lung metastases (HR = 1.53;
95 %CI 1.16–2.02) and the inability to achieve a clinical
benefit under a previous taxane therapy (HR = 1.50;
95 %CI 1.07–2.11) were the only 3 independent prognos-
tic factors of this population.
Focusing on the TN subgroup, the overall response
rate (ORR) was significantly higher in the TN population
(respectively 26.9 % vs. 22.8 %, p = 0.002) compared with
non-TN breast cancers. However, the OS and the TTP
were significantly lower (respectively, 8.3 months versus
11.9 months, p = 0.049, HR [95 % CI] = 1.46 [1.01–2.12];
2.1 months versus 4.3 months, p = 0.0004, HR [95 % CI] =
1.80 [1.32–2.45]) in the TN population.
Discussion
To our knowledge, our study is the largest international
multicentre retrospective study of EM use in heavily pre-
treated breast cancer patients. Our results confirm the
EM efficacy and safety in the daily care treatment of
heavily pretreated MBC patients, with a population ex-
posed to a median of four prior lines of chemotherapy.
The results of our study are comparable to those of the
pivotal EMBRACE phase III trial [13]. The two popula-
tions appeared relatively similar regarding the median
age (59 versus 55 years old) and the metastatic sites dis-
tribution (Table 4). The rate of HER2+ tumours was dis-
cretely lower in our population (10.2 % versus 16 %)
while the rate of TN tumours was slightly higher (22.5 %
versus 18 %) in the EMBRACE trial. TN tumours
seemed to respond better to the treatment, as we
observed an increased ORR in the TN subpopulation
compared with other biological subgroups (p = 0.002).
However OS and TTP were significantly lower. More-
over, HER2 positivity appeared as a predictive factor,
with 57.7 and 33.9 % CBR for HER2+ and HER2-
tumours, respectively. These results, which strikingly dif-
fer from the previous results from randomized trials, in
which none of the patients received concomitant trastu-
zumab, may be due to the nearly systematic use of tras-
tuzumab in association with EM in our population.
Indeed, in these studies, HER2 had no impact on EM
Table 4 Comparative evaluation between the EMBRACE and
the ERIBEX studies
EMBRACE ERIBEX
Population
Patients (n) 503 (EM) 258
Age (years) 55 59
Triple-negative tumour (%) 18 22.5
HER2+ tumour (%) 16 10.2
Prior hormonal therapy (%) 85 76.7
Prior anthracycline or taxane
treatment (%)
99 100
Prior capecitabine treatment (%) 73 90.7
Median prior metastatic
chemotherapies; n (range)
4 (1–7) 4 (1–9)
Metastatic sites
Bone (%) 61 68.2
Liver (%) 60 67.4
Node (%) 44 45.7
Lung (%) 38 38
Chemotherapy
Median number of EM cycles (range) 5 (1–23) 5 (1–19)
Efficacy
Median overall survival (month,
95 %CI)
13.1 11.2 (9.3–12.12
Median progression-free survival
(month, 95 %CI)
3.7 3.8 (3.2–4.2)
Overall response rate (%) 12 26
Clinical benefit rate 23 36
Safety
Side effects (grade 1–4, %) 99 94.2
Side effects most commonly encountered
Asthenia (%) 54 60.9
Neutropenia (%) 52 38.4
Peripheral Neuropathies (%) 35 43
Nausea (%) 35 10.5
Alopecia (%) 45 19.4
Grade 3 toxicity (%) 36.2 39.5
Grade 4 toxicity (%) 27.2 17
Grade 3–4 neutropenia 21 %/24 % 20.9 % grade 3–4
Grade 3-/4 peripheral neuropathy 8 %/<1 % 3.9 % grade 3–4
Treatment discontinuation due to
toxicity (%)
13 13.1
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efficacy [11, 13]. A recent phase II study evaluating the
safety and efficacy of the EM – trastuzumab association
in a first-line metastatic setting demonstrated a good
safety profile and an interesting 71.2 % ORR [14]. The
efficacy of this treatment combination could explain our
results and warrant further evaluation of this association.
Nevertheless, other studies will be needed to thoroughly
assess these differences in a clinical behaviour. The pro-
portion of patients with HR+ tumour was higher in our
study compared with the EMBRACE trial (73.3 % versus
64 %). Almost all these patients had previously been
treated with hormone therapy (97.3 %). Considering
the independent prognostic value of the HR+ status
in our population, this fact could explain the rela-
tively similar OS results obtained compared with the
EMBRACE trial patients, this favourable prognostic
factor counter-balancing the classical lower results of
retrospective studies due to the lack of selection in a
daily-care setting population. Also, some recent pre-
clinical data showed that EM may have some additive
antitumoral effect on estrogen-stimulated ER-positive
breast cancers [15].
Our population was heavily pretreated, as EM was ini-
tiated as a fifth-line of treatment, a line comparable to
that of the EMBRACE study. The anthracyclines and/or
taxanes pretreatment rate was comparable to the one in
the phase III study, reflecting the high adherence of the
participating institutions to breast cancer care recom-
mendations [3]. In addition, for the majority of patients
pretreated with taxanes, the best response rate (CR or
PR) observed in our study was 51.6 %, with 82.1 % CBR
under taxane therapy, defining a population of patients
showing good primary taxanes sensitivity. As taxanes
and EM share the same cellular site of action, this
parameter appears to be a logical predictive variable
of EM sensitivity. This assumption was verified in our
series, as patients without evidence of primary taxane
sensitivity in a previous line appeared to have statisti-
cally lower CBR and TTP under EM in multivariate
analysis. However, this result needs to be confirmed
in a separate independent population. Also, the
capecitabine pretreatment rate was greater in our
study (90.7 %) compared with the rate reported in the
EMBRACE study (73 %).
To date, no clinical study demonstrated the superiority
of EM compared to capecitabine. The phase III study
conducted by Kaufman et al. comparing EM to capecita-
bine did not show a statistically significant superiority of
EM over capecitabine in terms of OS and PFS, in a
population of patients who had received up to two previ-
ous lines of chemotherapy for metastatic disease (includ-
ing anthracycline and taxane) [10, 11]. In the EMBRACE
study, the EM group of patients was predominantly
capecitabine-pretreated, which may explain the choice of
capecitabine use before EM in routine clinical practice.
The convenience provided by an oral administration of
capecitabine may also explain its frequent use prior to
EM treatment.
Considering the efficacy issue, our results also ap-
peared globally similar to the results of the pivotal phase
III EMBRACE trial, with an OS of 11.2 and 13.1 months
respectively, and a PFS of 3.8 and 3.7 months, respect-
ively (Table 4). Interestingly, the ORR and CBR in our
retrospective, unselected study were relatively higher
compared with the EMBRACE study results (25.2 %
versus 12 % and 36.1 % versus 23 % respectively). Even if
no definitive conclusion can be issued from such an
indirect comparison, these results are interesting as
clinical practice results frequently appear less favourable
than pivotal trials results. In our study, EM treatment
was most of the time initiated at full dose (79.1 %).
Major reported cause of dose reduction was liver dys-
function. At the same time, percentage of prescription of
primary or secondary G-CSF prophylaxis was relatively
low (15.1 and 12.4 % respectively). These results could
possibly be explained by the choice of considering lower
doses of EM instead of using a G-CSF prophylaxis in
2 weeks over 3 schedules.
Treatment discontinuations due to EM toxicity were
relatively rare in our experience. Similarly, only few hos-
pitalizations and transfusions were required, demonstrat-
ing a good safety profile for the treatment. Alopecia was
Table 5 Summary of data published from phase III-IV trials on eribulin mesylate in metastatic breast cancer
Study (years) Phase Treatment Patients (n) OS (months) PFS (months) DOR (months) OR (%) Ref.
Cortes et al. (2011) [13] III Eribulin mesylate vs TPC 508 vs 254 13.1 3.7 3.9 13 [6]
Kaufman et al. (2012) [10] III Eribulin mesylate vs Capecitabine 554 vs 548 15.9 4.2 4.1 11 [10]
Ramaswami et al. (2014) [16] IV Eribulin mesylate 25 5.89 4.08 - 16 [16]
Poletti et al. (2014) [17] IV Eribulin mesylate 27 8 - 2.5 9 [17]
Gamucci et al. (2014) [18] IV Eribulin mesylate 133 14.3 4.4 5.2 21.1 [18]
Rasmussen et al. (2014) [19] IV Eribulin mesylate 44 - - - 12.5 [19]
Present study IV Eribulin mesylate 258 11.2 3.8 4.4 26
DOR Duration Of Response, OR Objective Response, OS Overall Survival, PFS Progression-free survival, TPC Treatment of physician’s choice
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relatively rare in our series (19.4 % vs. 45 % in the
EMBRACE study). This low alopecia frequency could
be linked to preventive measures routinely used in
our centres, such as the use of a cooling helmet dur-
ing treatment. Another possible explanation is the
more frequent use of capecitabine in the previous
therapeutic line, leaving a greater proportion of pa-
tients without grade 2 alopecia at initiation of the
EM treatment. The overall safety profile of our series
appears otherwise comparable to the results of the
EMBRACE study (Table 4).
Our study shows the limitations commonly observed
in retrospective studies (many items are not defined
from a predefined study protocol, the study is lacking a
central immunohistochemistry lecture…). However, the
greatest strength of our study is that it represents a large
data from a cohort of patients not included in clinical
trials, thus better reflecting the real-life patient popula-
tion in terms of comorbidities and disease extension.
Table 5 summarizes the main results of the presently
published data on EM in metastatic breast cancer, in-
cluding the pilot phase III EMBRACE trial [13], the
study reported by Kaufman et al. comparing EM with
capecitabine [10], together with recent retrospective
studies performed in daily care conditions published in
2014, as well as our study data, giving consistent results
to ensure the use of EM in the heavily pretreated MBC
setting, in terms of clinical efficacy and with a favourable
efficacy/safety ratio.
Conclusion
The evaluation of new drugs in current practice, outside
clinical trials, remains a key element of the evaluation of
their efficacy and safety after large pivotal studies. The
results showed by current practice could reveal to be dif-
ferent from the results obtained during the clinical trials
step, usually because of the heterogeneity of the analysed
population treated in routine conditions and under less
stringent selection than that of the trials. In our study,
EM appears to be an effective new-line treatment in
heavily pretreated MBC patients, with a favourable effi-
cacy/safety ratio. These encouraging results compare
favourably with those obtained in the pivotal phase III
EMBRACE study and with more recent retrospective
studies. They comfort the use of EM in the heavily pre-
treated MBC setting. Tumour biology, primary taxanes
sensitivity and metastatic sites could represent useful
predictive and prognostic factors in this population.
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